The Tetrahydroisoquinoline Derivative SP9 Exhibits Antiviral Activity Against PEDV and MHV

Read full text Summarise with VIRAT
Authors: Junhai Zhu, Yuting Jiang, K. W. Yang, Fei Gao, Wenbao Qi, Lihong Huang, Yue Wang
Cited by: 0
References: 37

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Coronaviruses exhibit high mutation rates and cross‐species transmissibility, posing a persistent threat to human and animal health and underscoring the urgent need for antivirals that can compensate for the limited crossprotection afforded by current vaccines. In this study, we synthesized a tetrahydroisoquinoline alkaloid (THIQA) derivative, 2‐[2‐(4‐chlorophenyl)ethyl]‐6,7‐dimethoxy‐1‐methyl‐1,2,3,4‐THIQ (SP9), and evaluated its antiviral activity against two phylogenetically distinct coronaviruses: porcine epidemic diarrhea virus (PEDV, α‐genus) and murine hepatitis virus (MHV, β‐genus). In vitro, SP9 dose‐dependently inhibited viral RNA synthesis, progeny virion production, and viral protein expression in both viruses. Time‐of‐addition analyses and dsRNA‐labeling assays localized the antiviral blockade at the replication stage. Mechanistically, SP9 disrupted autophagic flux by preventing autophagosome–lysosome fusion. In a lethal MHV‐challenge mouse model, SP9 significantly increased survival and accelerated bodyweight recovery. Together, these results identify SP9 as a novel coronavirus inhibitor that targets host autophagy, providing a promising lead for further optimization of tetrahydroisoquinoline (THIQ)‐based antivirals.

Fields of Study & Subjects

Animal Virus Infections Studies SARS-CoV-2 and COVID-19 Research interferon and immune responses

Publication details

Journal / source
Transboundary and Emerging Diseases
Volume
2026
Issue
1
Publication date
1 January 2026
Language
EN